|Strategies for Optimizing Care in MDS Based on Level of Risk|
Olatoyosi Odenike, MD, and Eunice S. Wang, MD
|Release Date: October 31, 2018|
Expiration Date: October 31, 2019
When decisions are made on MDS treatment, prognostic risk is determined using many patient-specific factors. With MDS therapies continuing to evolve, oncology nurses are challenged to stay up-to-date with recent treatment advances in which therapies are tailored based on patients being classified as having high- or low-risk disease. To appropriately manage MDS, patients must understand the impact of their level of risk on their treatment.
Oncology nurses are at the forefront of providing supportive care to patients when new therapies and treatment plans are initiated. They must balance potential benefits with tolerability and risks for side effects. In this activity, Dr. Olatoyosi Odenike discusses treatment strategies for low-risk MDS and evaluates how recent advances and emerging options are impacting the current standard of care. Dr. Eunice S. Wang summarizes strategies for the appropriate use of several different types of drug therapies and discusses clinical trial data that will help guide the management of high-risk MDS patients.Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Onconova Therapeutics Inc.
|Begin, Earn CreditView Only, No Credit|